Mohammad W Bahar

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 6

Top Topics

Electron Microscopy

Helicobacter Pylori Infection

Recombinant Human

Top Venues

Communications biology

This page only lists publications with an associated author ORCID identifier.

Publications

Mohammad W Bahar, Veronica Nasta, Helen Fox, Lee Sherry, Keith Grehan, Claudine Porta, Andrew J Macadam, Nicola J Stonehouse, David J Rowlands, Elizabeth E Fry, David I Stuart
Publisher Correction: A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation. Communications biology 5 (1) (2022)
Lee Sherry, Keith Grehan, Jessica J Swanson, Mohammad W Bahar, Claudine Porta, Elizabeth E Fry, David I Stuart, David J Rowlands, Nicola J Stonehouse
Production and Characterisation of Stabilised PV-3 Virus-like Particles Using Pichia pastoris . Viruses 14 (10) (2022)
Mohammad W Bahar, Veronica Nasta, Helen Fox, Lee Sherry, Keith Grehan, Claudine Porta, Andrew J Macadam, Nicola J Stonehouse, David J Rowlands, Elizabeth E Fry, David I Stuart
Publisher Correction: A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation. Communications biology 5 (1) (2022)
Mohammad W Bahar, Veronica Nasta, Helen Fox, Lee Sherry, Keith Grehan, Claudine Porta, Andrew J Macadam, Nicola J Stonehouse, David J Rowlands, Elizabeth E Fry, David I Stuart
A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation. Communications biology 5 (1) (2022)
Mohammad W Bahar, Veronica Nasta, Helen Fox, Lee Sherry, Keith Grehan, Claudine Porta, Andrew J Macadam, Nicola J Stonehouse, David J Rowlands, Elizabeth E Fry, David I Stuart
Publisher Correction: A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation. Communications biology 5 (1) (2022)
Mohammad W Bahar, Claudine Porta, Helen Fox, Andrew J Macadam, Elizabeth E Fry, David I Stuart
Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. NPJ vaccines 6 (1) (2021)